会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明申请
    • Serum Biomarkers for Diagnosing Liver Fibrosis and Method for Measuring the Same
    • 用于诊断肝纤维化的血清生物标志物及其测量方法
    • US20100323374A1
    • 2010-12-23
    • US12618882
    • 2009-11-16
    • Chun-Chia ChengShui-Cheng LeeShiao-shiun Guan
    • Chun-Chia ChengShui-Cheng LeeShiao-shiun Guan
    • G01N33/53G01N33/92C07K14/00
    • G01N33/6893G01N33/576G01N2800/085
    • Disclosed are serum biomarkers for diagnosing liver fibrosis and methods for measuring the same. The serum biomarkers obtained from human serum include alpha2-macroglobulin (“A2M”), vitamin D binding protein (“VDBP”), apolipoprotein AI (“ApoAI”). The methods involve with immunoassay using specific antibodies to detect the biomarkers, including enzyme-linked immunosorbent assay (“ELISA”), radio immune assay (“RIA”) and flexible multi-analyte profiling (“xMAP”). ELISA, RIA or xMAP is used to measure changes of protein concentration for the specific protein biomarkers in serum for diagnosing liver fibrosis with suffering hepatitis B or C or other liver diseases. The measurement is safe and accurate. The method can be used before and after treatment of liver fibrosis. Thus, it is possible to achieve early diagnosis and treatment advocated in the preventive medicine.
    • 公开了用于诊断肝纤维化的血清生物标志物及其测量方法。 从人血清获得的血清生物标志物包括α2-巨球蛋白(“A2M”),维生素D结合蛋白(“VDBP”),载脂蛋白AI(“ApoAI”)。 该方法包括使用特异性抗体进行免疫测定以检测生物标志物,包括酶联免疫吸附测定(“ELISA”),放射免疫测定(“RIA”)和柔性多分析物分析(“xMAP”)。 ELISA,RIA或xMAP用于测量血清中特异性蛋白质生物标志物的蛋白质浓度变化,以诊断患有乙型肝炎或C型肝炎或其他肝脏疾病的肝纤维化。 测量安全准确。 该方法可用于肝纤维化治疗前后。 因此,可以实现预防医学中倡导的早期诊断和治疗。